P0620: Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn’s Disease. Data from the ENEIDA registry.ECCO'25Year: 2025
Authors: Piñero, G.S.(1)*;Nos, P.(2);Ricart, E.(3);Calafat , M.(1);Riestra , S.(4);Mesonero, F.(5);Iglesias-Flores, E.(6);Pascual-Moreno, I.(7);Vera, I.(8);Martín-Arranz, M.D.(9);De Castro, L.(10);Taxonera, C.(11);Rivero, M.(12);Guardiola, J.(13);Arranz Hernandez, L.(14);Arias Garcia, L.(15);Varela, P.(16);Giordano, A.(17);Gisbert, J.P.(18);Barrio, J.(19);Calvet, X.(20);Gutiérrez-Casbas, A.(21);García-López, S.(22);Gargallo-Puyuelo, C.J.(23);Huguet, J.M.(24);Moraleja, I.(25);Pérez-Calle, J.L.(26);Bujanda, L.(27);Zabana, Y.(28);Ramos, L.(29);Sierra , M.(30);Carpio, D.(31);Barreiro-de-Acosta, M.(32);Lorente , R.(33);Bermejo, F.(34);González-Lama, Y.(35);Navarro-Llavat, M.(36);Márquez, L.(37);Mañosa, M.(1);Domènech, E.(1);
(1)Hospital Universitari Germans Trias I Pujol, Gastroenterology, Badalona, Spain;(2)Hospital Universitario y Politécnico de la Fe, Gastroenterology, Valencia, Spain;(3)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Reina Sofía de Córdoba, Gastroenterology, Córdoba, Spain;(7)Hospital Clinic Universitari de Valencia, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain;(9)Hospital Álvaro Cunqueiro, Gastroenterology, Pontevedra, Spain;(10)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(11)Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain;(12)Hospital Universitario Marques de Valdecilla, Gastroenterology, Santander, Spain;(13)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(14)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(15)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(16)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(17)Hospital Universitari de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(18)Hospital Universitario de la Princesa, Gastroenterology, Madrid, Spain;(19)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(20)Consorci Corporació Sanitària Parc Taulí de Sabadell, Gastroenterology, Sabadell, Spain;(21)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(22)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(23)Hospital Clínico Universitario "Lozano Blesa", Gastroenterology, Zaragoza, Spain;(24)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(25)Hospital Universitario de Galdakao, Gastroenterology, Galdakao, Spain;(26)Hospital Universitario Fundación de Alcorcón, Gastroenterology, Alcorcón, Spain;(27)Hospital Universitario Donostia, Gastroenterology, Donostia, Spain;(28)Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain;(29)Hospital Universitario de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain;(30)Complejo Asistencial Universitario de León, Gastroenterology, León, Spain;(31)Complexo Hospitalario de Pontevedra, Gastroenterology, Pontevedra, Spain;(32)Hospital Clínico Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(33)Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain;(34)Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain;(35)Hospital Universitario Doce de Octubre, Gastroenterology, Madrid, Spain;(36)Hospital de Sant Joan Despì Moisès Broggi, Gastroenterology, Barcelona, Spain;(37)Hospital del Mar de Barcelona, Gastroenterology, Barcelona, Spain; on behalf of the ENEIDA project of GETECCU.
P0621: Effectiveness and Safety of Induction Therapy with Upadacitinib for the Treatment of Perianal Crohn’s Disease : Real-World Data from a GETAID Multicentre Cohort Study.ECCO'25Year: 2025
Authors: Richard, N.(1)*;Altwegg, R.(2);Seksik, P.(3);Nancey, S.(4);Nachury, M.(5);Laharie, D.(6);Amiot, A.(7);Vuitton, L.(8);Peyrin-Biroulet, L.(9);Allez, M.(10);Rouillon, C.(11);Coffin, B.(12);Pelletier, A.L.(13);Uzzan, M.(14);Amil, M.(15);Hupé, M.(16);Fumery, M.(17);Bozon, A.(2);
(1)Univ Rouen Normandie- INSERM- ADEN UMR1073- "Nutrition- Inflammation and microbiota-gut-brain axis"- CHU Rouen, Department of Gastroenterology, F-76000 Rouen, France;(2)CHU of Montpellier, Department of Gastroenterology, Montpellier, France;(3)CRSA- Sorbonne Université- INSERM- APHP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(4)CHU of Lyon, Department of Gastroenterology, Lyon, France;(5)CHU of Lille, Department of Gastroenterology, Lille, France;(6)CHU de Bordeaux- Hôpital Haut-Lévêque- Université de Bordeaux, Department of Gastroenterology, Bordeaux, France;(7)Hôpitaux Universitaires Bicêtre- AP-HP- Université Paris Saclay, Department of Gastroenterology, Le Kremlin Bicêtre, France;(8)UMR 1098- University of Franche-Comté, Department of Gastroenterology, Besançon, France;(9)Nancy University Hospital- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(10)Hôpital Saint-Louis - APHP- Université Paris Cité- INSERM U1160, Gastroenterology Department, Paris, France;(11)Caen University Hospital, Department of Gastroenterology, Caen, France;(12)AP-HP Nord- Hôpital Louis Mourier, Department of Gastroenterology, Colombes, France;(13)CHU Bichat-Claude Bernard, Department of Gastroenterology, Paris, France;(14)Henri Mondor Hospital- Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs- Paris Est Créteil University UPEC- AP-HP, Gastroenterology Department, Créteil, France;(15)La Roche Sur Yon Hospital, Department of Gastroenterology, La Roche Sur Yon, France;(16)Univ. Grenoble Alpes / CHU Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology department, Grenoble, France;(17)Amiens University Hospital- and PeriTox- Université de Picardie, Department of Gastroenterology, Amiens, France;
1. Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966-1980. doi:10.1056/NEJMoa2212728
2. Colombel JF, Lacerda AP, Irving PM, et al. Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials. Clin Gastroenterol Hepatol. 2024;0(0). doi:10.1016/j.cgh.2024.08.032
P0622: Total emulsifier intake, but not ultra-processed food consumption is higher in patients with Inflammatory Bowel Disease compared to healthy controlsECCO'25Year: 2025
Authors: Wellens, J.(1)*;Debrauwere, M.(2);Hoekx, S.(1);Vanderstappen, J.(1);De Maegd, E.(2);Vissers, E.(2);Ferrante, M.(1);Verstockt, B.(1);Vermeire, S.(1);Sabino, J.(1);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and Metabolism- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium;
1. Chen J, Wellens J, Kalla R, et al. Intake of ultra-processed foods is associated with an increased risk of Crohn’s disease: a cross-sectional and prospective analysis of 187,154 participants in the UK Biobank. J Crohn’s Colitis. Published online 2022:187. doi:10.1093/ecco-jcc/jjac167
2. Wellens J, Vanderstappen J, Hoekx S, et al. DOP86 FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results. J Crohn’s Colitis. 2024;18(Supplement_1):i235-i237. doi:10.1093/ecco-jcc/jjad212.0126
P0623: Vedolizumab clearance as a predictor of remission in inflammatory bowel disease: a real-world pharmacokinetic studyECCO'25Year: 2025
Authors: Markovic, S.(1);Kralj, D.(1)*;Knezevic Ivanovski , T.(1);Kalaba, A.(1);Odanovic, O.(1);Homsek, A.(2);Svorcan, P.(1);Vucicevic, K.(2);
(1)Clinical Center University Hospital "Zvezdara", Gastroenterology and Hepatology Department, Belgrade, Serbia;(2)Faculty of Pharmacy – University of Belgrade, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade, Serbia; OPTYMAB studygroup
1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
2. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab for Crohn's disease. N Engl J Med. 2013;369:711–21.
3. Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in IBD. Clin Gastroenterol Hepatol. 2018;16:1937-1946.
P0624: Adherence to a Care Pathway for Inflammatory Bowel Disease in the Southwest region of the NetherlandsECCO'25Year: 2025
Authors: Visser, E.(1,2)*;Allers, S.(3);van Linschoten, R.(4);Bodelier, A.(5);Fitzpatrick, C.(6);de Jong, V.(7);Vermeulen, H.(8);Verweij, E.(9);van der Wiel, S.(10);van der Horst, D.(11);van der Woude, C.J.(12);van Noord, D.(1);West, R.L.(1);
(1)Franciscus, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus MC, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(3)Erasmus University Rotterdam, Health Policy & Management, Rotterdam, The Netherlands;(4)Erasmus MC, Family Medicine, Rotterdam, The Netherlands;(5)Amphia Hospital, Gastroenterology & Hepatology, Breda, The Netherlands;(6)IJsselland Hospital, Gastroenterology & Hepatology, Capelle aan de IJssel, The Netherlands;(7)Albert Schweitzer Hospital, Gastroenterology & Hepatology, Dordrecht, The Netherlands;(8)Ikazia Hospital, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(9)Maasstad Hospital, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(10)Reinier de Graaf Gasthuis, Gastroenterology & Hepatology, Delft, The Netherlands;(11)Crohn & Colitis NL, Crohn & Colitis NL, Woerden, The Netherlands;(12)Radboud UMC, Healthcare Related Education, Nijmegen, The Netherlands; Southwest Netherlands IBD Study Group
P0625: Impact of TMPT genotype on Azathioprine side effects and durability in a cohort of pediatric patients with Inflammatory Bowel Diasease: a real life study.ECCO'25Year: 2025
Authors: Di Sario, F.(1)*;Galeazzi, T.(2);Castaldo, P.(3);Magi, S.(3);Franceschini , E.(4);Gatti, S.(2);
(1)Università Politecnica delle Marche, Departement of Pediatrics, Ancona AN, Italy;(2)Università Politecnica delle Marche, Department of Pediatrics, Ancona, Italy;(3)Università Politecnica delle Marche, Department of Biomedical Sciences and Public Health, Ancona, Italy;(4)Azienda Ospedaliero Universitaria delle Marche, Department of Pediatrics, Ancona, Italy;
P0626: One year outcomes of upadacitinib in Crohn’s disease in a large real-world cohort.ECCO'25Year: 2025
Authors: Ramos Belinchon, C.(1)*;Plevris, N.(1);Elford, A.(1);Gros, B.(1,2);Constantine-Cooke, N.(3,4);Arnott, I.D.(1);Lees, C.W.(1,3);
(1)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Hospital Universitario Reina Sofía, Department of Gastroenterology and Hepatology, Cordoba, Spain;(3)University of Edinburgh, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom;(4)University of Edinburgh, MRC Human Genetics Unit, Edinburgh, United Kingdom;
P0627: Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Oral Resolvin E1-based Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy VolunteersECCO'25Year: 2025
Authors: Danese, S.(1)*;Siegmund, B.(2);Peyrin-Biroulet, L.(3);Verstockt, B.(4);Dubinsky, M.(5);Newman, R.(6);Thomas, H.(7);Guttendorf, R.(7);Lipper, R.(8);Steinberg, J.(9);Paperiello, B.(9);Jennings, T.(9);Jordan, D.(9);Parkinson, J.(9);Mathias, G.(9);Sands, B.(10);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)Charité – Universitätsmedizin Berlin, Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(3)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Icahn School of Medicine at Mount Sinai Medical Center, Division of Pediatric Gastroenterology and Nutrition, New York NY, United States;(6)CMAX Clinical Research Pty Ltd, Phase 1 Unit, Adelaide, Australia;(7)Aclairo Pharmaceutical Development Group, Pathology and DMPK, Sterling Virginia, United States;(8)Back Cove Pharma, Pharmaceutical Sciences, Waldoboro Maine, United States;(9)Thetis Pharmaceuticals LLC, Medical Affairs, Essex Connecticut, United States;(10)Icahn School of Medicine at Mount Sinai Medical Center, Division of Gastroenterology, New York NY, United States;
P0628: Patient preferences towards treatment attributes in Inflammatory Bowel Disease: a Brazilian cohort studyECCO'25Year: 2025
Authors: Argollo, M.(1)*;Queiroz, N.(2);Kurtz de Mello, M.(3);Senra, J.(4);Rosa, B.(4);Barreto, T.(5);
(1)Federal University of São Paulo, Department of Gastroenterology, São Paulo, Brazil;(2)Hospital Santa Cruz, IBD Unit, Curitiba, Brazil;(3)Universidade do Vale do Itajaí, Department of Gastroenterology, Itajaí, Brazil;(4)Takeda Pharma, Evidence Generation and Publications - Medical Affairs, São Paulo, Brazil;(5)Takeda Pharma, Gastro Immunology Medical Affairs, São Paulo, Brazil;
P0629: A scoping review of evidence-based dietary guidance and guidelines published by national and international organisations on Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Dimakis, I.K.(1);Kapsoritakis, A.(1);Argyriou, K.(1);Manolakis, A.(1);Grammatikopoulou, M.(1);Gkikas, K.(2);Gerasimidis, K.(2);Androutsos, O.(3);Svolos, V.(4)*;
(1)University of Thessaly, Department of Gastroenterology- University Hospital of Larissa, Larisa, Greece;(2)University of Glasgow, School of Medicine, Glasgow, United Kingdom;(3)Lab of Clinical Nutrition and Dietetics, Department of Nutrition and Dietetics- School of Physical Education- Sport Science and Dietetics- University of Thessaly, Trikala, Greece;(4)University of Thessaly, Department of Nutrition and Dietetics- School of Physical Education- Sport Science and Dietetics- University of Thessaly, Trikala, Greece;
P0630: Are women with inflammatory bowel disease at risk of abnormal cervix cytology? -results of retrospective studyECCO'25Year: 2025
Authors: Tulewicz-Marti, E.(1)*;Lewandowski, K.(2);Karłowicz, K.(2);Maciejewska, K.(2);Sierakowska, I.(2);Szweda, H.(3);Rydzewska, G.(2);
(1)National Medical Institute of the Ministry of the Interior and Administration- Warsaw- Poland, Department of Gastroenterology and Internal Medicine, Warsaw, Poland;(2)National Medical Institute of the Ministry of the Interior and Administration, Department of Gastroenterology and Internal Medicine, Warsaw, Poland;(3)Institute of Mother and Child, Department of Obstetrics and Gynecology, Warsaw, Poland;
P0631: Short-term effectiveness of risankizumab in patients with Crohn´s Disease: Experience in our centreECCO'25Year: 2025
Authors: Valdés Delgado, T.(1);Rodríguez Gallardo, M.(1)*;Maldonado Pérez, B.(1);Belvis Jiménez, M.(1);Castro Laria, L.(1); Argüelles Arias, F.(2);
(1)Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;(2)University of Seville-Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;
P0632: Analysis of serological responses to SARS-Cov-2 vaccination in patients with Inflammatory Bowel Disease in India identifies low BMI as an independent determinant of vaccine non-responseECCO'25Year: 2025
Authors: Wong, S.Y.(1)*;Moran, H.R.(1);Elgood-Hunt, G.(2);Stolle, L.(3);Giselbrecht, E.(1);Wellens, J.(4);Ahuja, V.(5);Virmani, S.(5);Kedia, S.(5);Dutta, U.(6);Sinha, S.K.(6);Sharma, V.(6);Samanta, J.(6);Shah, J.(6);Singh, A.K.(6);Kaur, H.(7);Colombel, J.F.(1);Thompson, C.(8);Satsangi, J.(9);
(1)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Ludger Ltd, Culham Science Centre- Abingdon- OX14 3EB, Oxford, United Kingdom;(3)Warwick Medical School WMS- Coventry CV4, Division of Medical Sciences, Warwick, United Kingdom;(4)Leuven University Hospitals, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(6)Postgraduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarh, India;(7)Postgraduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarah, India;(8)Warwick Medical School- University of Warwick, Division of Biomedical Sciences, Warwick, United Kingdom;(9)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;
(1) Wong SY, Wellens J, Helmus D, et al. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium. Inflamm Bowel Dis. 2023;29(11):1693-1705. doi:10.1093/ibd/izad097
P0633: Real World Outcomes of Upadacitinib Induction Therapy for Patient with Inflammatory Bowel Disease in KoreaECCO'25Year: 2025
Authors: Ye, B.D.(1)*;Kim, M.K.(2);Hong, S.W.(2);Hwang, S.W.(1);Park, S.H.(1);Yang, D.H.(2);Byeon, J.S.(2);Myung, S.J.(2);Yang, S.K.(1);
(1)Asan Medical Center- University of Ulsan College of Medicine, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;(2)Asan Medical Center- University of Ulsan College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;
1. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–2128.
2. Loftus EV, Jr., Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023;388:1966–1980.
P0634: Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World StudyECCO'25Year: 2025
Authors: MocciMD FRCP, G.(1)*;Scaldaferri, F.(2);Napoltitano, D.(2);Pugliese, D.(2);Maconi, G.(3);Pica, R.(4);Savarino, E.(5);Costa, F.(6);Ceccarelli, L.(6);Marzo, M.(7);Elisei, W.(8);Lombardi, G.(9);Ribaldone, D.G.(10);Bertani, L.(11);Rodino, S.(12);Orrù, G.(13);Bodini, G.(14);Pranzo, G.(15);Scarcelli, A.(16);Luppino, I.(17);Ferronato, A.(18);Spagnuolo, R.(19);Gravina, A.G.(20);Pellegrino, R.(21);Vespere, G.(22);Allegretta, L.(23);Fanigliuolo, L.(24);Grossi, L.(25);Cortellini, F.(26);Piergallini, S.(27);Capone, P.(28);Gaiani, F.(29);Mucherino, C.(30);D'Ascoli, B.(31);Colucci, R.(32);Onidi, F.M.(1);Usai Satta, P.(33);Picchio, M.(34);Papa, A.(35);Tursi, A.(36);
(1)ARNAS G. Brotzu, Division of Gastroenterology, Cagliari, Italy;(2)Policlinico Universitario “A. Gemelli” Foundation, Department of Medical and Surgical Sciences, Rome, Italy;(3)“L. Sacco” University Hospital, Department Biomedical and Clinical Sciences, Milan, Italy;(4)“S. Pertini” Hospital, Division of Gastroenterology- IBD Unit, Rome, Italy;(5)Azienda Ospedale-Università di Padova AOUP, Gastroenterology Unit, Padua, Italy;(6)Pisa University Hospital, IBD Unit- Department of General Surgery and Gastroenterology, Pisa, Italy;(7)“Veris-Delli Ponti” Hospital, Division of Gastroenterology, Scorrano, Italy;(8)A.O. “S. Camillo-Folanini”, Division of Gastroenterology, Rome, Italy;(9)AORN “Cardarelli”, Division of Gastroenterology, Naples, Italy;(10)University of Turin- IBD Unit- "A.O.U. Citta della Salute e della Scienza di Torino", Department of Medical Sciences- Division of Gastroenterology, Turin, Italy;(11)Azienda USL Toscana Nord Ovest, Division of Gastroenterology- “Felice Lotti” Hospital-, Pontedera, Italy;(12)“Ciaccio-Pugliese” Hospital, Division of Gastroenterology, Catanzaro, Italy;(13)University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italy;(14)IRCCS "San Martino" Hospital- University of Genoa, Department of Internal Medicine and Medical Specialties- Division of Gastroenterology, Genoa, Italy;(15)"Valle D’Itria” Hospital, Ambulatory for IBD Treatment, Martina Franca, Italy;(16)“San Salvatore” Hospital, Division of Gastroenterology, Pesaro, Italy;(17)“Annunziata” Hospital, Division of Gastroenterology, Cosenza, Italy;(18)ULSS7 Pedemontana, Digestive Endoscopy Unit, Santorso, Italy;(19)University of Catanzaro, Department of Health Science, Catanzaro, Italy;(20)University of Campania "Luigi Vanvitelli"-, Department of Precision Medicine- Hepatogastroenterology and Digestive Endoscopy Unit-, Naples, Italy;(21)University of Campania "Luigi Vanvitelli"-, Department of Precision Medicine- Hepatogastroenterology and Digestive Endoscopy Unit, Naples, Italy;(22)ASL Na1, Division of Gastroenterology- “Ospedale del Mare”, Naples, Italy;(23)“Santa Caterina Novella” Hospital, Division of Gastroenterology, Galatina, Italy;(24)“S.S. Annunziata” Hospital, Division of Gastroenterology, Taranto, Italy;(25)“Spirito Santo” Hospital- “G d'Annunzio” University, Gastroenterology Unit, Pescara, Italy;(26)“Infermi” Hospital, Division of Gastroenterology, Rimini, Italy;(27)A. Murri” Hospital, Division of Gastroenterology, Fermo, Italy;(28)T. Maresca” Hospital, Division of Gastroenterology, Torre del Greco, Italy;(29)University of Parma, Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery, Parma, Italy;(30)Azienda Ospedaliera “S. Anna e S. Sebastiano”, Division of Gastroenterology-, Caserta, Italy;(31)“Madonna delle Grazie” Hospital, Division of Gastroenterology, Matera, Italy;(32)Digestive Endoscopy Unit, “San Matteo degli Infermi” Hospital, Spoleto, Italy;(33)ARNAS G Brotzu, Division of Gastroenterology, Cagliari, Italy;(34)“P. Colombo” Hospital- ASL Roma 6, Division of General Surgery, Velletri, Italy;(35)Policlinico Universitario “A. Gemelli” Foundation- IRCCS, Digestive Diseases Centre CEMAD- Department of Medical and Surgical Sciences, Rome, Italy;(36)Asl BAT, Territorial Gastroenterology Service, Andria, Italy; IN-IBD (Italian Network of Inflammatory Bowel Disease)
P0635: Degree of interest in using a cognitive-behavioral therapy application for fatigue management and related factors among outpatients with inflammatory bowel diseaseECCO'25Year: 2025
Authors: Tanaka, M.(1)*;Kawakami, A.(1);Wakai, S.(1);Takai, M.(2);Sakagami, K.(3);Ito, H.(3);
(1)Institute of Science Tokyo, Dep. Adult Health Nursing, Tokyo, Japan;(2)Institute of Science Tokyo Hospital, Nursing department, Tokyo, Japan;(3)Kinshukai Infusion Clinic, Gastroenterology, Osaka, Japan;
P0636: Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance studyECCO'25Year: 2025
Authors: Magro, F.(1)*;Peyrin-Biroulet, L.(2);Biedermann, L.(3);Sands, B.E.(4);Danese, S.(5);Dulai, P.S.(6);Dubinsky, M.(7);Tilg, H.(8);Siegmund, B.(9);Hisamatsu, T.(10);Shan, K.(11);Jacobstein, D.(12);Cataldi, F.(13);Rabbat, C.(13);Vermeire, S.(14);
(1)Faculty of Medicine- University of Porto, CINTESIS@RISE Department of Biomedicine, Porto, Portugal;(2)INFINY Institute- INSERM NGERE- CHRU Nancy, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(3)University Hospital Zurich, Department of Gastroenterology & Hepatology, Zurich, Switzerland;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, San Raffaele, Italy;(6)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(7)Mount Sinai Kravis Children’s Hospital, Pediatric GI and Nutrition, New York, United States;(8)Medical University, Department of Gastroenterology- Hepatology- Endocrinology & Metabolism, Innsbruck, Austria;(9)Charité Universitätsmedizin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(10)Kyorin University School of Medicine, Department of Gastroenterology & Hepatology, Tokyo, Japan;(11)Abivax, Biometrics, Paris, France;(12)Abivax, Clinical Development, Paris, France;(13)Abivax, Medical Affairs, Paris, France;(14)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
1. Vermeire S, et al. J Crohns Colitis. 2023; 17: 1689-16972.
2. Vermeire S, et al. The Lancet Gastroenterology & Hepatology. 2022; 7: 1024-1035.
P0637: Ebrasodebart (Ent001) First in Human trial in healthy volunteers: pharmacokinetic results and predicted therapeutic concentrations to preserve mucosal healing in patients with Ulcerative ColitisECCO'25Year: 2025
Authors: Zangarini, M.(1)*;Marin, V.(1);Maucci, R.(1);Stabile, M.(1);Di Sanza, C.(1);Maestroni, A.(2);Amabile, G.(1);Nardini, C.(1);D'Addio, F.(2);Fiorina, P.(2);Olson, L.M.(1);Canducci, F.(1);Porzio, S.(1);
(1)Enthera Srl, Enthera, Milan, Italy;(2)Università degli Studi di Milano, Pediatric Clinical Research Center Invernizzi-Biomedical and Clinical Science, Milan, Italy;
P0638: Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD studyECCO'25Year: 2025
Authors: Sands, B.E.(1)*;Colombel, J.F.(1);Rubin, D.T.(2);Schreiber, S.(3);Siegel, C.A.(4);Yarur, A.(5);Danese, S.(6);Kang, A.(7);Kim, D.H.(7);Lee, Y.N.(7);Hanauer, S.B.(8);
(1)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York NY, United States;(2)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago IL, United States;(3)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(4)Dartmouth-Hitchcock Medical Center, Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Lebanon NH, United States;(5)Cedars Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute, Los Angeles CA, United States;(6)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(7)Celltrion- Inc., Global Medical Division, Incheon, Korea- Republic Of;(8)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago IL, United States;
1. Velikova T, et al. Antibodies. 2024;13(1):16.
2. Baert F, et al. N Engl J Med. 2003;348:601-608.
3. Colombel JF, et al. J Crohns Colitis. 2024;18(suppl 1):i1614-1615.
P0639: Population pharmacokinetics of subcutaneous vedolizumab in Crohn’s disease and Ulcerative ColitisECCO'25Year: 2025
Authors: Vreman, N.(1)*;Anjie, S.I.(2);Gecse, K.B.(2);Lowenberg, M.(2);D'Haens, G.R.A.M.(2);Mathôt, R.A.A.(1);
(1)Amsterdam UMC, Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
1. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188-202. doi:10.1111/APT.13243
2. Gisleskog PO, Karlsson MO, Beal SL. Use of Prior Information to Stabilize a Population Data Analysis. J Pharmacokinet Pharmacodyn. 2002;29(6).
3. D’Haens G, Rosario M, Polhamus D, et al. Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis. Expert Review of Clinical Pharmacology. 2024;17(4):403-412. doi:10.1080/17512433.2024.2318465